Market Overview

4 Takeaways On Pfizer's Latest Coronavirus Data

Share:
4 Takeaways On Pfizer's Latest Coronavirus Data

The data shows more positives about Pfizer’s (NYSE: PFE) coronavirus vaccine candidate and remains in-line with its German partner BioNTech’s (NASDAQ: BNTX) study, according to Cantor Fitzgerald Securities.

The Pfizer Analyst: Louise Chen maintained an Overweight rating on Pfizer with a $53 price target. 

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

The Pfizer Takeaways: Chen named the following in a note as key takeaways from the update Pfizer issued Monday:

  • Preliminary data indicates that PFE's mRNA-based vaccine was able to stimulate antibody as well as T-cell responses at low dose levels. 
  • Pfizer could initiate Phase a 2b/3 study with its lead candidate as early as this month. 
  • Pfizer's data further demonstrated the ability of BNT162b1 to elicit high SARS CoV-2 neutralizing titers.
  • The initial German trial results demonstratem— for the first time for the BNT62b1 candidate — a concurrent induction of high level CD4+ and CD8+ T cell responses against the SARS-CoV-2 RBD. 

Overall, the data suggests that BNT162b1 could potentially be administered safely, with a manageable tolerability profile, she said. 

“Data from both the German and U.S. Phase 1/2 studies will be used by the two companies to determine a dose level and select among multiple vaccine candidates to seek to progress to an anticipated large, global Phase 2b/3 safety and efficacy trial,” Chen said. 

The companies expect to have 100 million doses manufactured by the end of the year.

To that end, BioNTech and Pfizer would work jointly to distribute the vaccine worldwide, Chen said. 

PFE, BNTX Price Action: Pfizer shares were trading 1.08% higher at $36.63 at last check Monday, while BioNTech shares were higher by 3.10% at $87.89. 

Photo by Coolcaesar via Wikimedia

Latest Ratings for PFE

DateFirmActionFromTo
Jul 2020Morgan StanleyMaintainsEqual-Weight
Jul 2020UBSMaintainsNeutral
Jul 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!

Posted-In: Cantor FitzgeraldAnalyst Color Biotech Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
DOWTruist SecuritiesMaintains55.0
SBUXJP MorganMaintains80.0
AAPLCitigroupMaintains125.0
BCDAAlliance Global PartnersInitiates Coverage On11.5
EURNJonesTradingInitiates Coverage On
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com